The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NPHC | +100% | -98.04% | -54.43% | -100% |
| S&P | +13.95% | +78.35% | +12.25% | +541% |
Nutra Pharma Corp. operates as a bio pharmaceutical company. The firm engages in the acquisition, licensing and commercialization of pharmaceutical products and technologies & homeopathic and ethical drugs for the management of pain, neurological disorders, autoimmune and infectious diseases. Its products are Cobroxin, which is used for an over-the-counter pain reliever designed to treat moderate to severe chronic pain and Nyloxin Extra Strength, which is used for stronger versions of Cobroxin. The company was founded on February 1, 2000 and is headquartered in Plantation, FL.
No news articles found for Nutra Pharma.
| Q3 2024 | YOY Change | |
|---|---|---|
| Revenue | $109.47K | 0.0% |
| Gross Profit | $49.55K | 0.0% |
| Gross Margin | 45.27% | 0.0% |
| Market Cap | $7.60K | 0.0% |
| Net Income | -$260.68K | 0.0% |
| EBITDA | -$161.75K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2024 | YOY Change | |
|---|---|---|
| Net Cash | $0.00K | 0.0% |
| Accounts Receivable | $33.20K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $165.15K | 0.0% |
| Short Term Debt | $9.54M | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -204.35% | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | $19.07K | 0.0% |
| Operating Free Cash Flow | $19.07K | 0.0% |
| Metric | Q1 2024 | Q2 2024 | YoY Change | |
|---|---|---|---|---|
| Price to Sales | 1.49 | 1.76 | - | |
| Enterprise Value to EBITDA | -52.30 | -64.69 | - | |
| Total Debt | $9.54M | $9.70M | $9.71M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
